Alzheimer Disease Clinical Trials

135 studies are recruiting for alzheimer disease in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 5

1. Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia

   This project aims to examine the efficacy of remote, caregiver-led tES/brain stimulation intervention targeted to improve memory, mobility, and executive functioning among older adults with mild cognitive impairment or mild dementia.

   Stage

   Not phased

   Ages

   55 and older

   Site

   Hinda and Arthur Marcus Institute for Aging Research, Boston, Massachusetts

   Run by

   Hebrew SeniorLife

   See if you can join NCT05661084 on ClinicalTrials.gov

2. ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

   The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

   Stage

   Not phased

   Ages

   50 to 85

   Site

   Delray Medical Center & Florida Atlantic University, Delray Beach, Florida

   Locations

   10 in total

   Run by

   InSightec

   See if you can join NCT03671889 on ClinicalTrials.gov

3. MR Evaluation of Cerebrospinal Fluid (CSF) Dynamics

   The Researchers are trying to test a MR imaging method for detection of Cerebral Spinal Fluid (CSF) flow in the brain to help diagnosis and better understand diseases that affect brain function.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mayo Clinic, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT04099823 on ClinicalTrials.gov

4. Trial to Reduce Antimicrobial Use in Nursing Home Residents With Alzheimer's Disease and Other Dementias 2.0

   The goal of this pragmatic cluster randomized clinical trial is to compare management of suspected infection in nursing home residents with dementia The main questions it aims to answer whether residents with dementia in nursing homes randomized to use a multicomponent intervention to optimize susp…

   Stage

   Not phased

   Ages

   60 to 106

   Site

   Hebrew SeniorLife, Boston, Massachusetts

   Run by

   Hebrew SeniorLife

   See if you can join NCT05950607 on ClinicalTrials.gov

5. Testing the Effects of a Text Message Caregiver Support Intervention for Latinos

   The goal of this randomized clinical trial it to test the efficacy of CuidaTEXT, the first Alzheimer's disease and Related Dementias (ADRD) caregiver support intervention to capitalize on text messaging, among Latinos. Researchers will compare those who receive the CuidaTEXT intervention to those w…

   Stage

   Not phased

   Ages

   18 to 100

   Site

   University of Kansas Medical Center, Fairway, Kansas

   Run by

   University of Kansas Medical Center

   See if you can join NCT06728436 on ClinicalTrials.gov

6. Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

   The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.

   Stage

   Phase 4

   Ages

   60 and older

   Site

   Mayo Clinic, Jacksonville, Florida

   Locations

   2 in total

   Run by

   Mayo Clinic

   See if you can join NCT03821857 on ClinicalTrials.gov

7. I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms

   This study is a randomized, controlled trial (RCT) to evaluate the effect of Brain CareNotes (a mobile health application) on the burden experienced by unpaid caregivers of patients with dementia and on the behavioral and psychological symptoms of dementia (BPSD) displayed by care recipients. Over …

   Stage

   Not phased

   Ages

   18 and older

   Site

   IU Health, Indianapolis, Indiana

   Locations

   2 in total

   Run by

   Indiana University

   See if you can join NCT05733520 on ClinicalTrials.gov

8. Low-Intensity Focused Ultrasound (LIFU) Neuromodulation

   This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with mild cognitive impairment ( MCI) due to Alzheimer's disease.

   Stage

   Not phased

   Ages

   45 to 85

   Site

   Rockefeller Neuroscience Institute at West Virginia University, Morgantown, West Virginia

   Run by

   Ali Rezai

   See if you can join NCT05997030 on ClinicalTrials.gov

9. HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms

   This randomized controlled trial study aims to evaluate a revised hearing care intervention for older adults with Alzheimer's Disease and Related Dementias (ADRD). The community-delivered hearing care intervention utilizes tailored strategies to assess impact on communication, neuropsychiatric symp…

   Stage

   Not phased

   Ages

   60 to 100

   Site

   Johns Hopkins Memory and Alzheimer's Treatment Center, Baltimore, Maryland

   Run by

   Johns Hopkins University

   See if you can join NCT06930560 on ClinicalTrials.gov

10. Open-Label Extension Protocol to SNK01-AD01 Study

    Open-Label Extension Protocol to SNK01-AD01 Study

    Stage

    Phase 2

    Ages

    40 to 85

    Site

    Behavioral Research Specialists, LLC, Glendale, California

    Run by

    NKGen Biotech, Inc.

    See if you can join NCT07228078 on ClinicalTrials.gov

11. Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside

    This project's main goal is to use state-of-the-art passive sensing techniques to identify digital biomarkers that relate to bioenergetic changes in the brain due to nicotinamide riboside supplementation in those with mild cognitive impairment and mild Alzheimer's dementia.

    Stage

    Not phased

    Ages

    18 to 89

    Site

    McLean Hospital, Belmont, Massachusetts

    Run by

    Mclean Hospital

    See if you can join NCT05245903 on ClinicalTrials.gov

12. PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620

    The investigators will compare [18F]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal subjects.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Perelman Center for Advance Medicine, Philadelphia, Pennsylvania

    Run by

    University of Pennsylvania

    See if you can join NCT05456503 on ClinicalTrials.gov

13. Assess Fibrin in Brains With AD/ADRD

    The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.

    Stage

    Phase 1

    Ages

    55 to 90

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT05336695 on ClinicalTrials.gov

14. Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy

    The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease. * Will this blood test have the abilit…

    Stage

    Not phased

    Ages

    60 to 90

    Site

    Cumberland Medical Center, Crossville, Tennessee

    Locations

    6 in total

    Run by

    Covenant Health, US

    See if you can join NCT07222280 on ClinicalTrials.gov

15. A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

    The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to th…

    Stage

    Not phased

    Ages

    60 and older

    Site

    Rehabilitation & Neurological Services, Huntsville, Alabama

    Run by

    Eli Lilly and Company

    See if you can join NCT06566170 on ClinicalTrials.gov

16. Improving Memory in Alzheimer's Disease With Noninvasive Brain Stimulation

    The investigators will evaluate the theory that Alzheimer's disease-related memory impairment derives from the inefficient orchestration of rhythmic activity at the level of large-scale cortical networks. The results as expected to elucidate AD-related pathophysiology and set groundwork for the dev…

    Stage

    Not phased

    Ages

    50 to 100

    Site

    677 Beacon St. Room 308, Boston, Massachusetts

    Run by

    Boston University Charles River Campus

    See if you can join NCT06094192 on ClinicalTrials.gov

17. OCT Angiography and NRAI in Dementia

    The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. Detect retinal blood vessel and blood flow changes in participants with dementia. 2. Detect amyloid protein deposits in the retinas of participants with dementia.

    Stage

    Not phased

    Ages

    55 and older

    Site

    Oregon Health & Science University, Portland, Oregon

    Run by

    Oregon Health and Science University

    See if you can join NCT03761381 on ClinicalTrials.gov

18. Imaging Biomarkers in Preclinical and Symptomatic AD

    The purpose of this research study is to evaluate adult children of parents with and without Alzheimer's disease which represent an ideal population for investigating the biological changes that precede the clinical onset of AD. The investigators will be imaging the brain to detect the presence of …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Tammie L. S. Benzinger, MD, PhD

    See if you can join NCT04134923 on ClinicalTrials.gov

19. Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease

    CMK-0301 is a multi-site, randomized clinical trial to evaluate the safety and efficacy of [F-18]Flornaptitril-PET (F-18 FNT-PET) for the prediction of clinical progression of Mild Cognitive Impairment (MCI) with either Suspected Chronic Traumatic Encephalopathy (CTE) or Alzheimer's Disease (AD). T…

    Stage

    Phase 3

    Ages

    45 and older

    Site

    Endeavor Health Systems, Evanston, Illinois

    Run by

    CereMark Pharma, LLC

    See if you can join NCT06254469 on ClinicalTrials.gov

20. Alzheimer Prevention Trials (APT) Webstudy

    The goal of the Alzheimer Prevention Trials (APT) Webstudy is to accelerate enrollment for Alzheimer's disease (AD) clinical trials by identifying and tracking individuals who may be at higher risk for developing AD dementia.

    Stage

    Not phased

    Ages

    50 to 85

    Site

    Https://Www.Aptwebstudy.Org, San Diego, California

    Run by

    University of Southern California

    See if you can join NCT03638583 on ClinicalTrials.gov

21. Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease

    The investigators will study performance on computerized cognitive tasks in healthy participants of different ages to gather normative data for newly developed computerized cognitive tests. These tests are designed to permit the early detection of individuals at risk of age-related cognitive declin…

    Stage

    Not phased

    Ages

    18 to 89

    Site

    Neurobehavioral Systems, Inc., Berkeley, California

    Run by

    Neurobehavioral Systems, Inc.

    See if you can join NCT04800588 on ClinicalTrials.gov

22. First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia

    This is a first in human study that will assess the safety and diagnostic performance of [18F]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer's disease (AD)…

    Stage

    Phase 1

    Ages

    40 to 75

    Site

    China Basin, UCSF, San Francisco, California

    Run by

    David Wilson

    See if you can join NCT05374278 on ClinicalTrials.gov

23. Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease

    This is a research study to evaluate the safety of an investigational autologous cell product obtained from participant's own adipose tissue as a possible treatment for Alzheimer disease.

    Stage

    Phase 1

    Ages

    45 to 80

    Site

    Hoag Memorial Hospital Presbyterian, Newport Beach, California

    Run by

    Regeneration Biomedical, Inc.

    See if you can join NCT05667649 on ClinicalTrials.gov

24. NYSCF Scientific Discovery Biobank

    The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store th…

    Stage

    Not phased

    Ages

    0 and older

    Site

    New York Stem Cell Foundation Research Institute, New York, New York

    Run by

    New York Stem Cell Foundation Research Institute

    See if you can join NCT06203106 on ClinicalTrials.gov

25. Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy

    Electrical activity in the brain known as "gamma" brainwaves help connect and process information throughout the brain. These gamma waves are diminished in Alzheimer's disease. New research in Alzheimer's disease mouse models shows that exposure to light flickering at the rate of 40 flashes per sec…

    Stage

    Not phased

    Ages

    50 and older

    Site

    Andrey Vyshedskiy, Miami, Florida

    Run by

    Alzheimer's Light LLC

    See if you can join NCT03657745 on ClinicalTrials.gov